Skip to main content

Table 3 Insulin resistance indices according to lipodystrophy defined clinically and by FMR

From: Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance

Lipodystrophy defined clinically defined by FMR
  Total Without CL With CL P Without L With L P
HOMA-IR [median (IQR)] 1.9 (2.8) 1.7 (2.4) 2.1 (3.0) 0.229 1.6 (2.6) 2.8 (2.8) <0.001
HOMA-B [median (IQR)] 92.3 (106.4) 92.3 (91.1) 91.8 (117.5) 0.855 92.3 (96.1) 85.4 (120.8) 0.633
QUICKI [median (IQR)] 0.34 (0.06) 0.35 (0.06) 0.34 (0.06) 0.229 0.36 (0.07) 0.33 (0.05) <0.001
MATSUDA [median (IQR)] 4.8 (5.1) 5.0 (4.2) 4.7 (5.4) 0.735 5.9 (5.3) 4.1 (4.4) 0.002
Glucose [mg/dL, median (IQR)] 93.5 (26.0) 90.0 (23.0) 97.0 (35.5) 0.046 90.0 (23.0) 97.0 (35.5) 0.002
Insulin [μU/mL, median (IQR)] 8.1 (9.6) 7.9 (8.2) 9.0 (10.2) 0.365 7.5 (8.1) 10.1 (9.9) 0.003
A1c [% median (IQR)] 5.3 (0.7) 5.2 (0.6) 5.3 (0.9) 0.091 5.2 (0.6) 5.5 (0.9) 0.002
  1. (CL- clinical lipodystrophy; L- lipodystrophy).